J Bone Metab.
2021 Nov;28(4):339-341. 10.11005/jbm.2021.28.4.339.
Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab
- Affiliations
-
- 1Department of Orthopaedic Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
- KMID: 2523253
- DOI: http://doi.org/10.11005/jbm.2021.28.4.339
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Bone-modifying agents for bone metastasis in patients with breast cancer
- Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year
- Comparison of Denosumab and Zoledronic Acid in Postmenopausal Women With Osteoporosis: Bone Mineral Density (BMD) and Trabecular Bone Score (TBS)
- Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature
- Preventive Effects of Zoledronic Acid on Bone Metastasis in Mice Injected with Human Breast Cancer Cells
